Previously, it has been shown that E,-pim-1 transgenic mice are predisposed to T-celi lymphomas, whereas Ep,-myc transgenic mice are.predisposed to pre-B-cell lymphomas. Here we show that double-transgenic E,u-myc E,u-pim-1 mice exhibit pre-B-cell leukemia in utero. Upon transplantation into recipient mice, embryo-derived double-transgenic leukemic cells frequently progressed to highly malignant monoclonal tumors, indicating that additional (epi)genetic events had occurred during the progression of the disease.
The development of cancer is a multistep process of predominantly genetic and epigenetic events, the accumulation of which is directly correlated with the level of exposure to mutagens and with time (4, 8, 12, 17, 19) . This fact predicts that certain genotypes may predispose to cancer. Such genetic linkage has indeed been demonstrated by classical genetics and in vitro transformation assays (7, 14, 20) . Many of the genetic lesions have been shown to cause the activation of oncogenes or inactivation of tumor suppressor genes. Now that a number of these genes directly contributing to the tumorigenic process have been defined, we can predispose to cancer in a controlled and defined way by transgenesis (5, 6, 9) . Previously, we have demonstrated that E,u-pim-l transgenic mice, which express the pim-1 oncogene at elevated levels in their lymphoid compartments, are predisposed to T-cell lymphomas (3, 21) . In the preleukemic phase, lymphoid organs of E,u-pim-l transgenic mice do not show imbalances in the different subpopulations of cells, as analyzed by flow cytometric analysis, although a slight enlargement of the spleen is consistently observed. The occurrence of T-cell lymphomas, but not B-cell lymphomas, in E,u-pim-1 transgenic mice does not preclude the possibility that pim-1 also promotes B-cell lymphomagenesis, as was suggested by the proviral activation of pim-1 in B-cell lymphomas of some mouse strains (18) . T-cell lymphomagenesis in E,u-pim-1 transgenic mice can be strongly accelerated by infection of newborn mice with murine leukemia virus (21) . In over 95% of the tumors induced by murine leukemia virus in E,u-pim-1 mice, overexpression of either c-myc or N-myc was found as the result of the nearby integration of a provirus (21) . These results suggested, but did not prove, that pim-1 and myc directly synergize in lymphomagenesis, since one might argue that a high level of pim-1 expression only facilitates the activation of myc, perhaps by causing the expansion of a particular cell compartment. Previously, it has been demonstrated that Ep,-myc transgenic mice show a consistent enlargement of the pre-B-cell compartment with the concomitant predisposition to B-cell lymphomas (1, 2, 6, 10, 15 E,u-myc and E,u-pim-1 transgenic mice and show that pim-1 and c-myc directly synergize in lymphomagenesis.
E,u-pim-1 transgenic mice have been described previously (21) . For the generation of Eu-myc mice, an E,u-myc fusion gene, isolated from a plasmacytoma and generously provided by Suzanne Cory, was introduced into the germ line of mice by pronuclear injection of fertilized oocytes (11) recovered in cumulus from the oviducts of superovulated (CBA/BrA x C57BL/LiA)F1 females that had mated with Fl males. Transgenic founders were backcrossed with either (CBA/BrA x C57BL/LiA)F1 mice or with the C57BL/LiA parental strain.
The characteristics of the transgenic E,u-myc mouse lines obtained (186 and 187) are essentially the same as those described by Adams et al. (1, 2, 6, 10, 15) : the c-myc transgene is highly expressed in B cells but not in T cells or other somatic tissues (data not shown). Pre-B-cell lymphomas developed in 75% of the animals after a latent period of 2.5 to 12 months (Fig. 1) . The prelymphomatous state was characterized by an enlarged pre-B-cell comnpartment in which the pre-B cells aberrantly expressed Ia major histocompatibility complex class II surface antigens, as detected by flow cytometry using antibodies directed against T-and B-cell-specific surface markers (for a summary of markers, see reference 21), as was previously noted by Cory et al. (6, 15) . A third founder line, E,u-myc 188, expressed the c-myc transgene at extremely low levels, with the concomitant absence of a high tumor incidence (Fig. 1) . Table 1 summarizes the numbers of offspring with the different genotypes born from crosses between heterozygous E,u-pim-1 and E,u-myc mice. With the exception of one animal that died at 5 weeks of age, no viable pim-1 c-myc double-transgenic mice were found in litters from crossbreedings of pim-1 line 64 or 66 with E,u-myc line 186 or 187 (Fig. 1) . Most of the dead newborns that could be collected immediately after birth carried both transgenes. In contrast, double-transgenic offspring from crosses between the E,upim-1 lines and the low-expressor E,u-myc line 188 were viable and showed a low tumor incidence. To gain insight into the cause of the perinatal lethality of transgenic mice expressing both pim-1 and c-myc at high levels, 17-to 19-day-old embryos from matings between heterozygous E,u-pim-l and E,L-myc transgenic mice (lines 186 and 187) were collected, analyzed for the presence of the E,u-myc and % tumor free EpL-pim-1 transgenes, and examined histologically. Of these fetuses, 25% carried both transgenes ( Table 1 ). The gross morphology of the double-transgenic fetuses was normal. However, peripheral blood of these fetuses contained large numbers of blastoid cells of variable size (Fig. 2) . Histological examination of 17-to 19-day-old fetuses and placentas showed the involvement of predominantly liver and spleen but not of extraembryonic tissues. Whereas the liver exhibited a normal structure with an increased leukocyte cell density, the splenic architecture was hardly recognizable because of lymphomatous growth. Peripheral lymph nodes, Peyer's patches, and bone marrow did not show major alterations at this stage. However, accumulation of lymphoid cells was found at the base of the skull (between the hypophysis and the cochlear area), in the maxillary periosteal area, in the orbital-lining mesenchyme, in the venous plexus, and, incidentally, in cervical and cranial dermal mesenchyme. Immunohistochemistry revealed that the ex- panded cell population in the fetuses carried the B-cellspecific cell surface marker B220 (Fig. 3) (Fig. 1) .
Although these data show that pim-1 and c-myc synergize effectively in the induction of malignant pre-B-cell lymphomas in utero, the question remains as to whether overexpression of pim-1 and c-myc in the B-cell lineage early in embryonic development suffices for malignant transformation. If observed. Their heterogeneous appearance suggested that they represent a polyclonal population of cells, although this heterogeneity might also reflect a limited capacity to differentiate. Furthermore, since the leukocyte count varied considerably among 17-to 19-day-old double-transgenic embryos, additional stochastic events may occur early in embryogenesis, thereby affecting the actual expansion of the embryonic lymphoid compartments. We were unable to sufficiently enrich the leukemic cells from these small blood samples for direct analysis. Moreover, it has been shown that normally certain DJ rearrangements predominate within the polyclonal B lineage (15) , thereby limiting the usefulness of these markers to directly determine the clonality of the expanded pre-B cells in the fetuses. Therefore, we used an indirect approach to get insight into the clonality of the leukemic cells of the fetuses. A cell suspension was prepared from the spleen and liver of one fetus, and aliquots were transplanted into 15 histocompatible (CBA/BR x C57BL/LiA)F1 hosts ( (B) . Note the abundance of B220-positive cells in the liver of the double-transgenic mouse. Immunohistochemistry was performed as described previously (13) . Thin sections obtained from paraffin-embedded embryos were stained with hematoxylin and eosin and additionally with Giemsa. lated from the individual tumors, and the Ig heavy-chain rearrangement pattern was determined by Southern blot analysis, using the joining region probe pJll (16) . Within a single recipient, Ig rearrangements, which probably are restricted to D-J joinings, were mostly identical in tumors from different anatomical sites. However, the rearrangement pattern differed among independent recipients inoculated with an aliquot of the same fetus (data not shown). This result strongly suggests that the transplanted tumors are derived from different ancestor cells, although we cannot formally exclude the possibility that cells from the same tumorigenic ancestor clone have undergone Ig rearrangements after transplantation. In either case transplantation has resulted in the selective outgrowth of only a limited number of (sub)clones.
Our data are most compatible with a model of tumorigenesis in which a polyclonal pre-B-cell proliferation, induced by the E,u-myc and E,u-pim-1 genes in the early embryo, is frequently followed or facilitated by additional (epi)genetic events leading to the formation of malignant cells. The stochastic nature of these events could explain the variation in the severity of the disease in 17-to 19-day-old fetuses and might also account for the lack of transplantability of some of the blood samples. Upon transplantation, additional selective forces then act on these cells, resulting in the outgrowth of further adapted subclones of tumor cells that are marked by different D-J joinings. The massive expansion of pre-B cells seen already around 17 to 19 days of gestation indicates that the proliferative impulse, mediated by the high expression of c-myc and pim-1, acts on the hematopoietic system from early in embryogenesis. Finally, it is noteworthy that the search for synergizing oncogenes by an in vivo protocol using provirus tagging in transgenic mice has resulted in the identification of c-myc and pim-1, two oncogenes that appear to display the strongest synergism in in vivo tumorigenesis reported to date.
